Replies to post #413869 on Amarin Corp Plc (AMRN)

[TalShu]

TCI1

QUOTE The issue is it is difficult to release this information when reimbursement discussions are ongoing in Europe and ROW. UNQUOTE

Would this still hold if Amarin adopted a "Population based health approach – subscription model": a cheaper price to cover the entire estimated patients in every county (single payor-system)?

JT used to say Vascepa is a volume deal.